曲美替尼
达布拉芬尼
医学
肿瘤科
黑色素瘤
内科学
阶段(地层学)
癌症研究
威罗菲尼
转移性黑色素瘤
遗传学
MAPK/ERK通路
生物
古生物学
激酶
作者
Alexander M. Menzies,Serigne Lo,Robyn P.M. Saw,Maria Gonzalez,Sydney Ch’ng,O E Nieweg,Kerwin F. Shannon,P M Ferguson,Jenny Lee,Louise Emmett,R Kapoor,R V Rawson,Jonathan R. Stretch,John F. Thompson,A J Spillane,Helen Rizos,R A Scolyer,Georgina V. Long
标识
DOI:10.1016/j.annonc.2024.05.002
摘要
Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report 5-year outcomes from the phase II NeoCombi trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI